Navigation Links
Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
Date:6/4/2009

onnection with the restructuring and costs associated with the restructuring. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the restructuring may result in additional costs or other negative results not currently anticipated. Moreover, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 will not have unforeseen safety issues or will have favorable results in the planned Phase II trial. Also, Anadys cannot provide any assurances that the FDA will concur with Anadys' proposed ANA598 Phase II trial design. In addition, Anadys' results may be affected by risks related to competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into collaborations around its product candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its product candidates, regulatory developments involving its product candidates and its ability to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... ON , April 23, 2015 /CNW/ - A ... sustainable packaging award from North America,s ... Brandcheck Competitor Comparison won Silver in the "Sustainability, ... The Brandcheck "Competitor Comparison" is a ... of North American and Global peers. This benchmarking ...
(Date:4/23/2015)... D.C. (PRWEB) April 23, 2015 ... D.C. region on April 4-17 as part of ... marks the fourth group of biotechnology startups to ... of Nizhny Novgorod (UNN) and the University of ... deepen ties between their respective universities in the ...
(Date:4/23/2015)... -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), ... serving the pharmaceutical, biotechnology and medical device industries, with ... the United States , today announced that ... of 2015 after the New York Stock Exchange closes ... morning, May 14, 2015 Shanghai time). The earnings release ...
(Date:4/23/2015)... LAKE FOREST, Calif. , April 23, 2015 ... provider of advanced cryogenic logistics solutions for the ... has further established its cryogenic logistics solutions within ... customer agreement with Yancey Farms to support the ... top German Sport horse Stallions. ...
Breaking Biology Technology:U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 4WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 2Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 3
... Ltd,(SWX: ARPN) announced today the results of a ... iclaprim and warfarin.,Warfarin is widely used for the ... to be well-controlled.The drug-drug interaction study,comprised 24 healthy ... with and without pre- and co-administration of iclaprim ...
... Acclaimed stem cell researcher Shinya Yamanaka, MD, PhD, ... have successfully reprogrammed human adult cells to function like ... much of the controversy and restrictions regarding generation of ... in the journal Cell, should accelerate the pace of ...
... - Appointment of Company Officers ... ... - 1 Stock ... Meeting held on,November 7 2007, Monica R. Brettler, Tush P. Nikollaj, Carl H. Rosner and,Arthur Roth were elected to ...
Cached Biology Technology:Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim 2Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim 3Shinya Yamanaka reprograms human adult cells 2CardioMag Announces Results of 2006 Annual Shareholders Meeting and Board Meeting 2
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a leading ... services, and Morpho, a leading supplier of biometric ... produce the market,s most advanced biometrically-enabled time clock, ... NXG time clock is setting a bold, new ... data for the small and mid-size employer. When ...
(Date:4/2/2015)... Germany , April 2, 2015 ... fingerprint tests DERMALOG by far outperforms the strongest ... always maintaining high accuracy, the system is capable ... Hence, the speed proves up to be ten ... faster than its runner-up performance.      ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... do undergraduate students gain valuable hands-on experience by participating ... contributions, examples of which are highlighted in the current ... a peer-reviewed journal published by Mary Ann Liebert, Inc. ... This special issue features a collection of papers ...
... Scientists at The Scripps Research Institute have designed a new ... drugs targeting a human metabolic enzyme believed to stimulate the ... new test, which the scientists call a simple assay, will ... for those that have potential to block the action of ...
... LA JOLLA, CA September 16, 2010 For Immediate ... been awarded a four-year, $5.1 million grant as part of ... development of the next generation of DNA sequencing technologies, which ... sequence a person,s DNA. With the new grant, ...
Cached Biology News:Undergraduate research highlighted in DNA and Cell Biology Journal 2Scripps scientists develop test providing new pathway for identifying obesity, diabetes drugs 2Scripps scientists develop test providing new pathway for identifying obesity, diabetes drugs 3Scripps research team wins $5.1 million to develop DNA sequencing technology 2
... The lyophilization stabilizer is designed to ... and for long-term storage. There ... ingredients. It is a convenient ... 7.2, and is superior to other ...
... The CERTOMAT IS, a true benchtop incubator-shaker, has ... Having a footprint of 540 x 680 ... large incubation chamber (370 x 505 x 510mm). ... the CERTOMAT IS is ideal for shaking applications ...
... TC-3000 is one of the smallest thermal cyclers ... choice of either the 0.5ml (20 samples) or ... , Fast heating and cooling rate of ... and high performance Fast track programming with ...
... StabilZyme HRP Conjugate Stabilizer is an aqueous ... and other non-toxic stabilizing chemicals in a ... 6.7. This product contains a ... 20 ppm Proclin 300 (Rohm and Haas ...
Biology Products: